Tomohiko Yoshida

Dr. Tomohiko Yoshida

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
TYTomohiko Yoshida
Tomohiko Yoshida
PSPaula H. Stern
Paula H. Stern

1 May 2009 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
ITIchiro Tatsuno
Ichiro Tatsuno
TSTakao Sugiyama
Takao Sugiyama
SSSawako Suzuki
Sawako Suzuki
TYTomohiko Yoshida
Tomohiko Yoshida
TTTomoaki Tanaka
Tomoaki Tanaka
YSYasushi Saito
Yasushi Saito
Objectives: Collagen vascular diseases requiring treatment with high-dose glucocorticoids are frequently complicated by vertebral fracture. We investigated the incidence of symptomatic vertebral fractures for 20 yr among patients who were treated with high-dose glucocorticoids in the Chiba-Shimoshizu Rheumatic Cohort. Methods: A total of 2631 patients with collagen vascular diseases (aged ≥18 yr) was registered between 1986 and 2006. The prevalence of symptomatic vertebral fracture was compared between the high-dose glucocorticoid group newly treated with high-dose glucocorticoids (≥20 mg/d prednisolone equivalent) (n = 700), and the non-glucocorticoid controls not treated with glucocorticoids (n = 194). Results: During the 20-yr study period, symptomatic vertebral fractures occurred more frequently in the high-dose glucocorticoid group (23.9%) than in the non-glucocorticoid controls (2.6%). According to a Kaplan-Meier analysis, the cumulative incidence of symptomatic vertebral fracture was significantly higher in the high-dose glucocorticoid group than in the non-glucocorticoid controls (P < 0.001). Stratified into age quartiles of the high-dose glucocorticoid group (age 18–31, 32–47, 48–59, and 60–88 yr), the patients had a markedly increased incidence of symptomatic vertebral fracture with aging. The hazard ratios were also significantly higher in the older age quartile of 60–68 than in the younger age quartile of 32–47 (P < 0.001 for trend). The hazard ratio was 26-fold higher in patients aged 60–88 than in patients aged 18–31 (P < 0.01). In the group with fractures, the treatment duration before fracture was negatively associated with the initial age (r = −0.6587; P < 0.001). Conclusions: The prevalence of symptomatic vertebral fractures was higher in the patients treated with high-dose glucocorticoids than the untreated controls. Vertebral fractures were age dependent in patients treated with high-dose glucocorticoids. Treatment duration before fracture incidence was significantly shorter in the older patients.

4 May 2009 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
TYTomohiko Yoshida
Tomohiko Yoshida
AFAyanna Flegler
Ayanna Flegler
AKAndrew Kozlov
Andrew Kozlov
PSPaula H. Stern
Paula H. Stern

24 August 2009 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
ZHZhendong Hong
Zhendong Hong
ASAlexandre Mello de Paula Silva
Alexandre Mello de Paula Silva
TYTomohiko Yoshida
Tomohiko Yoshida
LLLan Luan
Lan Luan
PSPaula H. Stern
Paula H. Stern
JKJohn B. Ketterson
John B. Ketterson

3 June 2009 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
ANAzusa Nagata
Azusa Nagata
TTTomoaki Tanaka
Tomoaki Tanaka
AMAsami Minezawa
Asami Minezawa
MPMasha Poyurovsky
Masha Poyurovsky
TMTakafumi Mayama
Takafumi Mayama
ITIchiro Tatsuno
Ichiro Tatsuno